Appeals panel upholds order for Tru Niagen to drop 'clinically proven' claims

An industry appeals panel has upheld a recommendation that Niagen Bioscience stop calling its Tru Niagen supplement "clinically proven" and discontinue several other health claims. The National Advertising Review Board (NARB), the appeals body inside BBB National Programs, ruled in a challenge brought by a competing manufacturer, Reus Research, according to a report published May 22, 2026 ^[1].

The National Advertising Division (NAD) first reviewed the advertising and recommended that Niagen drop the "clinically proven" wording, along with claims about immune health, brain health and heart health. Niagen appealed. The review board concluded the division had applied the right legal standard and left its recommendation in place ^[1]. The decision does not state how many claims were reviewed, set a dollar amount, or give a date by which the company must comply ^[1].

What the phrase requires

Asa Waldstein, founder and principal at Apex Compliance, a firm that advises supplement companies on regulatory and marketing compliance, said "clinically proven" is a strong claim that a shopper could read as meaning the product itself — or something very close in form, dose, strength and use — was studied and shown to deliver the stated result. A double-blind, placebo-controlled human trial is often the standard for that kind of statement, he said, and the evidence has to line up with what people actually take. He added that ingredient research can still be discussed, but that wording claiming clinical proof must stay tightly matched to the evidence behind it ^[1].

Regulation versus advertising

Niagen argued the statements were structure/function claims, a category the FDA oversees under the Dietary Supplement Health and Education Act of 1994. NAD saw it differently, pointing to Federal Trade Commission guidance that DSHEA status is a regulatory matter for the FDA and not a factor in deciding whether a health claim is misleading or properly supported ^[1]. The appeals panel agreed that the tests for advertising claims are separate from how the FDA treats structure/function claims ^[1].

Carlos Lopez, senior vice president and general counsel at Niagen, said the company was "deeply disappointed" and called the standard applied by the panel overly restrictive and inconsistent with supplement law, scientific practice and past advertising precedent ^[1]. Niagen argued the division critiqued studies one by one instead of weighing all the evidence together, and said the ruling "fundamentally shifts" the supplement landscape. The company said the question is how ad claims are interpreted, not whether its products are safe or well made ^[1].

Reus Research countered that the claims were broad, that the standards used matched earlier NAD and FTC precedent, and that Niagen was invoking substantiation principles it now attacks. Reus also said Niagen markets to older adults, who it described as potentially more vulnerable to unsupported claims ^[1]. Roman Miroedov, product development lead at Cata-Kor, said the bar for "clinically proven" is high however a company classifies a claim internally, and that the ruling confirms the consumer's understanding controls, not the advertiser's regulatory label ^[1].

The two companies have tangled before. Niagen challenged claims on Reus's Cata-Kor products; NAD found some were supported and others should be changed or dropped. Niagen called the later challenge against it "clearly retaliatory" ^[1].

Why it matters for patients

Anyone shopping for supplements can take one simple point from this case: how a product is regulated does not settle whether its advertising misleads. Reviewers look at what a reasonable buyer would understand from the ad ^[1]. That logic applies to supplements marketed with medical-sounding promises, including those sold alongside or as substitutes for prescription weight-management drugs.

The case itself involved a NAD+ supplement. Semaglutide, tirzepatide and orforglipron are not named anywhere in the ruling, and no product sold as a GLP-1 alternative appears in it ^[1]. The decision does not change the FDA-approved status, labeling or supply of any prescription GLP-1 medicine ^[1]. It also came from industry self-regulation rather than a government enforcement action; the panel thanked both companies for taking part ^[1].

What happens next

No compliance deadline has been disclosed, and it has not been reported whether Niagen will take the matter further ^[1].